Neurovations Awarded 6.9 million-Dollar Grant for Groundbreaking Educational Pain Research Program
Neurovations Awarded 6.9 million-Dollar Grant for Groundbreaking Educational Pain Research Program
Neurovations Awarded 6.9 million-Dollar Grant for Groundbreaking Educational Pain Research Program
NIH HEAL Initiative: Coordinating Center for National Pain Scientists Career Development Grant awarded to Neurovations Education Division CEO and Founder of Neurovations, Dr. Eric Grigsby NAPA, Calif., Oct. 13, 2022 /PRNewswire/ — Dr. Eric Grigsby, Founder and CEO of Neurovations, announced that Neurovations Education is the recipient of a 6.9 million-dollar grant from the Helping to End Addiction Long-term Initiative®, […]
NAPA, Calif., Sept. 28, 2022 /PRNewswire/ — Neurovations now offers transcranial magnetic stimulation (TMS) for the treatment of Major Depressive Disorder (MDD) — making it the first mental health provider of TMS Therapy in Napa Valley where mental health services are in high demand. TMS is used to activate areas of the brain that are underactive in depression. The addition of […]
Dr Eric Grigsby, CEO and Founder, Neurovations September is Pain Awareness Month. We want to raise awareness and provide resources for physicians and patients alike. Follow us this month for complimentary webinars, keynotes from the Napa Pain Conference and more. #painmanagement #physiotherapy #chronicillnes Facebook Twitter Linked In Instagram Youtube The post Pain Awareness Month appeared […]
September 8, 2022 Accurately and thoroughly describing your pain can help your health care provider give you better treatment. As a patient, you are encouraged to express any concerns, questions, or inquiries you may have about your pain. But, if you don’t know how to describe your pain this can become difficult. This article is […]
Napa Pain Institute is looking for a Nurse Practitioner who is or is committed to becoming, an expert and leader in care for patients with chronic pain and related neurological conditions. Today, the specialty of pain management is exploding with opportunities to help our patients. At Napa Pain Institute, we carefully establish the right diagnosis; […]
Dr. Katalin Karikó, co-inventor of the modified mRNA technology used in vaccines to prevent COVID-19 infection, keynotes the Napa Pain Conference August 23. 2022 Napa, CALIF, – Approximately 600 top scientists, interventional pain physicians, policy-makers, researchers and innovators gathered to attend the 29th Napa Pain Conference (NPC) in downtown Napa. “This year, we were honored […]
Job description We are hiring an experienced Infusion Nurse for Napa Surgery Center(NSC) and Napa Pain Institute. NSC is part of the Neurovations family headquartered in Napa, California in the heart of the California Wine Country. Are you ready to help us grow? Napa Surgery Center is a small physician-owned Ambulatory Surgery Center. We perform […]
Founder Dr. Eric Grigsby reveals new hybrid event to share knowledge broadly Tuesday, September 14, 2021 The Napa Pain Conference hosted its twenty-eighth meeting in downtown Napa this past week, making it the oldest running pain conference in the Western United States. Experts in pain management gathered including Nobel Laureate Elizabeth Blackburn, PhD as keynote […]
NeuroTech Reports by James Cavuoto, editor and publisher Several hundred pain clinicians attended the 28th Napa Pain Conference in Napa, CA earlier this month. The event, produced by Neurovations Education, took place at the Culinary Institute of America’s Copia facility, with participation from online attendees. Featured presenters at the event included Daniel Carr, professor emeritus […]
CEO and Founder Dr. Eric Grigsby Founder Dr. Eric Grigsby reveals new hybrid event to share knowledge broadly Tuesday, September 14, 2021 The Napa Pain Conference hosted its twenty-eighth meeting in downtown Napa this past week, making it the oldest running pain conference in the Western United States. Experts in pain management gathered including Nobel […]
Completion of enrollment for the Phase 2b study in osteoarthritis of the knee Clinical data presented at OARSI provides support for osteoarthritis program First patient dosed in the Phase 1/2a study in neuropathic pain NEW YORK–(BUSINESS WIRE)–Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation through immune modulation, today […]